...
首页> 外文期刊>電子情報通信学会技術研究報告. ニュ-ロコンピュ-ティング. Neurocomputing >TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer
【24h】

TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer

机译:TINAGL1和B3GALNT1是抑制非小细胞肺癌转移的潜在治疗靶基因

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Non-small cell lung cancer (NSCLC) remains lethal despite the development of numerous drug therapy technologies. About 8.5% to 90% of lung cancers are NSCLC and the 5-year survival rate is at best still below 50%. Thus, it is important to find drug target genes for NSCLC to develop an effective therapy for NSCLC. Integrated analysis of publically available gene expression and promoter methylation patterns of two highly aggressive NSCLC cell lines generated by in vivo selection was performed. We selected eleven critical genes that may mediate metastasis using recently proposed principal component analysis based unsupervised feature extraction. The eleven selected genes were significantly related to cancer diagnosis. The tertiary protein structure of the selected genes were inferred by Full Automatic Modeling System, a profile based protein structure inference software, to determine protein functions and to specify genes that could be potential drug targets. We identified eleven potentially critical genes that may mediate NSCLC metastasis using bioinformatic analysis of publically available data sets. These genes are potential target genes for therapy of NSCLC. Among the eleven genes, TINAGL1 and B3GALNT1 are possible candidates for drug compounds that inhibit their gene expression.
机译:尽管开发了许多药物治疗技术,但非小细胞肺癌(NSCLC)仍然具有致命性。大约8.5%至90%的肺癌是非小细胞肺癌,其5年生存率充其量仍低于50%。因此,重要的是找到用于NSCLC的药物靶基因以开发出用于NSCLC的有效疗法。对通过体内选择产生的两种高度侵袭性NSCLC细胞系的公众可获得的基因表达和启动子甲基化模式进行了综合分析。我们使用最近提出的基于无监督特征提取的主成分分析方法,选择了11个可能介导转移的关键基因。选择的11个基因与癌症诊断显着相关。所选基因的三级蛋白质结构由全自动建模系统(基于轮廓的蛋白质结构推断软件)推断,以确定蛋白质功能并指定可能成为潜在药物靶标的基因。我们使用可公开获得的数据集进行生物信息学分析,确定了11个潜在的关键基因,它们可能介导NSCLC转移。这些基因是用于治疗非小细胞肺癌的潜在靶基因。在这11个基因中,TINAGL1和B3GALNT1可能是抑制其基因表达的药物的候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号